🔎 Trials Near Me

Utama › Limfoma Bukan Hodgkin › South Carolina

Kajian klinikal Limfoma Bukan Hodgkin di South Carolina

5 kajian untuk Limfoma Bukan Hodgkin sedang mencari peserta di lokasi di South Carolina.

Bandar di South Carolina

Teks kajian rasmi (Bahasa Inggeris)

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • SC Cancer Specialists at St. Joseph's/Candler Bluffton, Bluffton
  • St. Joseph's/Candler Smith, Bluffton
  • Summit Cancer Care at St. Josph's/Candler Bluffton, Bluffton
  • dan 1 lagi
Mengambil pesertaFasa 2
Umur 12 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT02693535

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Medical University of South Carolina, Charleston
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 6 Jul 2026 · NCT01351545

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • AnMed Health Cancer Center, Anderson
  • Beaufort Memorial Hospital, Beaufort
  • Saint Joseph's/Candler - Bluffton Campus, Bluffton
  • dan 18 lagi
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06418204

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

  • Greenville Hospital System University Medical Center (ITOR), Greenville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Feb 2026 · NCT05892718

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Greenville
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.